You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AZ inks agreement with saRNA specialist VaxEquity

AstraZeneca (AZ) has announced a new agreement with Imperial College London spin-off VaxEquity to discover and develop self-amplifying RNA (saRNA) therapeutics.